Spyre Therapeutics, Inc. SYRE Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s financing cash flow?
- Spyre Therapeutics, Inc. (SYRE) reported financing cash flow of $12.26M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Spyre Therapeutics, Inc.'s financing cash flow increased by 9704.0% year-over-year, from $125K to $12.26M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s financing cash flow?
- Over 2 years (2023 to 2025), Spyre Therapeutics, Inc.'s financing cash flow has grown at a -9.1% compound annual growth rate (CAGR), from $373.61M to $309.03M.
- What does financing cash flow mean?
- This represents the net cash flow resulting from all financing activities, including equity issuance, debt transactions, and stock-based compensation adjustments. It indicates the company's ability to raise capital to fund its operations.